Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by American Century Companies Inc.

American Century Companies Inc. reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 49.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,523 shares of the company's stock after selling 88,727 shares during the quarter. American Century Companies Inc. owned about 0.09% of Neurocrine Biosciences worth $12,629,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Neurocrine Biosciences by 0.5% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 22,361 shares of the company's stock worth $3,052,000 after purchasing an additional 103 shares during the last quarter. Teacher Retirement System of Texas grew its stake in Neurocrine Biosciences by 14.8% in the 4th quarter. Teacher Retirement System of Texas now owns 30,812 shares of the company's stock worth $4,206,000 after acquiring an additional 3,974 shares during the period. First Financial Bankshares Inc raised its holdings in Neurocrine Biosciences by 51.9% in the 4th quarter. First Financial Bankshares Inc now owns 26,942 shares of the company's stock valued at $3,678,000 after acquiring an additional 9,208 shares during the last quarter. Harvest Fund Management Co. Ltd acquired a new position in Neurocrine Biosciences in the 4th quarter valued at $161,000. Finally, Xponance Inc. boosted its holdings in shares of Neurocrine Biosciences by 7.7% during the fourth quarter. Xponance Inc. now owns 27,067 shares of the company's stock worth $3,695,000 after purchasing an additional 1,941 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several analysts have commented on the company. Deutsche Bank Aktiengesellschaft started coverage on Neurocrine Biosciences in a report on Tuesday, February 11th. They issued a "hold" rating and a $138.00 price target for the company. JPMorgan Chase & Co. boosted their target price on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the company an "overweight" rating in a report on Wednesday, March 26th. UBS Group cut their price target on shares of Neurocrine Biosciences from $154.00 to $137.00 and set a "buy" rating on the stock in a research note on Friday. Morgan Stanley reiterated an "overweight" rating and issued a $150.00 price target (down previously from $185.00) on shares of Neurocrine Biosciences in a report on Friday, March 7th. Finally, HC Wainwright restated a "buy" rating and set a $185.00 price objective on shares of Neurocrine Biosciences in a report on Friday, February 21st. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $163.52.

Neurocrine Biosciences Stock Down 7.0 %

NBIX stock traded down $7.23 during trading on Friday, hitting $95.65. 2,452,044 shares of the company's stock traded hands, compared to its average volume of 1,000,883. The stock has a fifty day moving average price of $120.01 and a two-hundred day moving average price of $124.37. Neurocrine Biosciences, Inc. has a 52 week low of $93.59 and a 52 week high of $157.98. The stock has a market capitalization of $9.54 billion, a price-to-earnings ratio of 29.07, a price-to-earnings-growth ratio of 0.77 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. As a group, equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Neurocrine Biosciences declared that its Board of Directors has initiated a share buyback plan on Friday, February 21st that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 4.2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's leadership believes its stock is undervalued.

Insider Buying and Selling at Neurocrine Biosciences

In related news, CFO Matt Abernethy sold 2,558 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $116.86, for a total value of $298,927.88. Following the completion of the transaction, the chief financial officer now directly owns 34,775 shares of the company's stock, valued at $4,063,806.50. This represents a 6.85 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Kevin Charles Gorman sold 5,844 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $116.69, for a total value of $681,936.36. Following the completion of the sale, the director now owns 521,618 shares in the company, valued at approximately $60,867,604.42. This represents a 1.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 232,906 shares of company stock worth $33,869,030. 4.30% of the stock is owned by insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.